<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Newborn screening for inborn errors of metabolism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Newborn screening for inborn errors of metabolism</h1>
<div class="graphic"><div class="figure"><div class="ttl">Newborn screening for inborn errors of metabolism</div><div class="cntnt"><table cellspacing="0"><colgroup span="9" width="11%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Analyte</td> <td class="subtitle1" rowspan="2">Analytical platforms</td> <td class="subtitle1" colspan="3">Differential diagnosis</td> <td class="subtitle1" rowspan="2">Available second-tier test</td> <td class="subtitle1" rowspan="2">Initial confirmatory testing<sup>Δ</sup></td> <td class="subtitle1" rowspan="2">Urgency of clinical follow-up<sup>◊</sup></td> <td class="subtitle1" rowspan="2">ACT Sheet and ACMG algorithm links</td> </tr> <tr> <td class="subtitle2">Core conditions*</td> <td class="subtitle2">Secondary conditions*</td> <td class="subtitle2">Other conditions<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="9">Amino acids</td> </tr> <tr> <td class="indent1">Arginine (Arg)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Arginase deficiency</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> <li>Urine orotic acid</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Arginine.pdf" target="_blank">ACT Sheet for increased arginine (argininemia)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Arginine-Algorithm.pdf" target="_blank">ACMG algorithm for elevated arginine</a></li> </ul> </td> </tr> <tr> <td class="indent1">Argininosuccinic acid (ASA)</td> <td>MS/MS</td> <td> <ul> <li>Argininosuccinate lyase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> <li>Urine orotic acid</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Citrullinemia.pdf" target="_blank">ACT Sheet for elevated citrulline (amino acidemia/urea cycle disorder)</a></li> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Citrulline-Elevated.aspx" target="_blank">ACMG algorithm for elevated citrulline (amino acidemia)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Citrulline (Cit), elevated</td> <td>MS/MS</td> <td> <ul> <li>Citrullinemia type I (argininosuccinate synthetase <span class="nowrap_whitespace">deficiency)<sup>§</sup></span></li> <li>Argininosuccinate lyase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Citrullinemia type II (citrin <span class="nowrap_whitespace">deficiency)<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Pyruvate carboxylase deficiency</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> <li>Urine orotic acid</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Citrullinemia.pdf" target="_blank">ACT Sheet for elevated citrulline (amino acidemia/urea cycle disorder)</a></li> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Citrulline-Elevated.aspx" target="_blank">ACMG algorithm for elevated citrulline (amino acidemia)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Citrulline (Cit), reduced</td> <td>MS/MS</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Ornithine transcarbamylase deficiency</li> <li>Carbamoyl phosphate synthetase type I deficiency</li> <li>N-acetylglutamate synthetase deficiency</li> <li>MT-ATP6 related mitochondrial disease</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> <li>Urine orotic acid</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Decreased Citrulline Newborn Screening ACT Sheet.aspx" target="_blank">ACT Sheet for decreased citrulline</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Decreased-Citrulline-Algorithm.pdf" target="_blank">ACMG algorithm for decreased citrulline</a></li> </ul> </td> </tr> <tr> <td class="indent1">Glutamine/pyroglutamic acid (Gln/Pyrog)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Citrullinemia type II (citrin <span class="nowrap_whitespace">deficiency)<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>5-oxoprolinase or glutathione synthetase deficiency</li> <li>Ornithine transcarbamylase deficiency</li> <li>Carbamoyl phosphate synthetase type I deficiency</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> <li>Urine orotic acid</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Citrullinemia.pdf" target="_blank">ACT Sheet for elevated citrulline (amino acidemia/urea cycle disorder)</a></li> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Citrulline-Elevated.aspx" target="_blank">ACMG algorithm for elevated citrulline (amino acidemia)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Glycine (Gly)</td> <td>MS/MS</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Nonketotic hyperglycinemia</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Glycine in cerebrospinal fluid</li> </ul> </td> <td>Next business day</td> <td>N/A</td> </tr> <tr> <td class="indent1">Leucine/isoleucine/OH proline (Xle), elevated</td> <td>MS/MS</td> <td> <ul> <li>Maple syrup urine <span class="nowrap_whitespace">disease<sup>§</sup><sup>¥</sup></span></li> </ul> </td> <td>N/A</td> <td> <ul> <li>Pyruvate dehydrogenase component E3 deficiency (dihydrolipoamide dehydrogenase deficiency)</li> <li>Hydroxyprolinemia (hydroxy-L-proline oxidase deficiency)</li> </ul> </td> <td> <ul> <li>Allo-isoleucine</li> </ul> </td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Leucine.pdf" target="_blank">ACT Sheet for increased leucine (maple syrup urine disease)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Leucine-Algorithm.pdf" target="_blank">ACMG algorithm for elevated leucine</a></li> </ul> </td> </tr> <tr> <td class="indent1">Leucine/isoleucine/OH proline (Xle), reduced</td> <td>MS/MS</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Branched-chain ketoacid dehydrogenase kinase <span class="nowrap_whitespace">deficiency<sup>¥</sup></span></li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> </ul> </td> <td>Next business day</td> <td>N/A</td> </tr> <tr> <td class="indent1">Lysine (Lys)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>2;4-dienoyl-CoA reductase deficiency</li> </ul> </td> <td> <ul> <li>Alpha-aminoadipic semialdehyde synthase deficiency</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Next business day</td> <td>N/A</td> </tr> <tr> <td class="indent1">Methionine (Met)</td> <td>MS/MS</td> <td> <ul> <li>Cystathionine beta-synthase deficiency</li> </ul> </td> <td> <ul> <li>Methionine adenosyltransferase I/III, S-adenosylhomocysteine hydrolase, and glycine N-methyltransferase deficiencies</li> <li>Cobalamin metabolism defect complementation <span class="nowrap_whitespace">types C/D<sup>§</sup><sup>‡</sup></span></li> </ul> </td> <td> <ul> <li>Methylenetetrahydrofolate reductase deficiency</li> <li>Cobalamin metabolism defect complementation <span class="nowrap_whitespace">type D combined<sup>†</sup></span></li> <li>Cobalamin metabolism defect complementation <span class="nowrap_whitespace">types E/F/G/J/X<sup>‡</sup></span></li> </ul> </td> <td> <ul> <li>Total homocysteine</li> </ul> </td> <td> <ul> <li>Plasma amino acids</li> <li>Total homocysteine</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/MethionineHomocystinuria-CBS-Deficiency.aspx" target="_blank">ACT Sheet for elevated methionine +/– elevated homocysteine (homocystinuria [cystathionine beta-synthase deficiency (CBS deficiency)])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Methionine-Algorithm.pdf" target="_blank">ACMG algorithm for elevated methionine +/– elevated homocysteine</a></li> </ul> </td> </tr> <tr> <td class="indent1">Ornithine/asparagine (Orn/Asn)</td> <td>MS/MS</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Ornithine aminotransferase deficiency</li> <li>Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Urine amino acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Phenylalanine (Phe)</td> <td>MS/MS</td> <td> <ul> <li>Phenylketonuria (phenylalanine hydroxylase deficiency)</li> </ul> </td> <td> <ul> <li>Mild phenylalanine hydroxylase deficiency</li> <li>GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin synthase deficiencies</li> <li>Dihydropteridine reductase and pterin-4 alpha-carbinolamine dehydratase deficiencies</li> </ul> </td> <td> <ul> <li>Untreated maternal phenylketonuria**</li> </ul> </td> <td> </td> <td> <ul> <li>Plasma amino acids</li> <li>Urine pterins</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/PKU.aspx" target="_blank">ACT Sheet for elevated phenylalanine (phenylalanine hydroxylase deficiency [PAH])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Phenylalanine-Algorithm.pdf" target="_blank">ACMG algorithm for PAH deficiency (elevated phenylalanine)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Succinylacetone (SUAC)</td> <td>MS/MS</td> <td> <ul> <li>Tyrosinemia type I (fumarylacetoacetase deficiency)</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> <li>Alpha fetoprotein</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Tyrosinemia Newborn Screening ACT Sheet.aspx" target="_blank">ACT Sheet for increased tyrosine (tyrosinemia)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Tyrosine-Normal-Algorithm.pdf" target="_blank">ACMG algorithm for normal/elevated tyrosine, elevated succinylacetone</a></li> </ul> </td> </tr> <tr> <td class="indent1">Tyrosine (Tyr)</td> <td>MS/MS</td> <td> <ul> <li>Tyrosinemia type I (fumarylacetoacetase deficiency)</li> </ul> </td> <td> <ul> <li>Tyrosinemia type II (tyrosine aminotransferase deficiency)</li> <li>Tyrosinemia type III (4-hydroxyphenylpyruvate dioxygenase deficiency)</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Succinylacetone</li> </ul> </td> <td> <ul> <li>Plasma amino acids</li> <li>Urine organic acids</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Tyrosinemia Newborn Screening ACT Sheet.aspx" target="_blank">ACT Sheet for increased tyrosine (tyrosinemia)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Tryosine-Elevated-Algorithm.pdf" target="_blank">ACMG algorithm for elevated tyrosine, normal succinylacetone</a></li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="9">Acylcarnitines</td> </tr> <tr> <td class="indent1">Carnitine (C0), reduced</td> <td>MS/MS</td> <td> <ul> <li>Carnitine uptake defect (organic cation transporter 2 [OCTN2] deficiency)</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Untreated maternal cases of carnitine uptake defect, glutaric acidemia type [glutaryl-CoA dehydrogenase deficiency], 3-methylcrotonyl-CoA carboxylase <span class="nowrap_whitespace">deficiency<sup>¶¶</sup></span></li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Carnitine-Uptake-Defect-ACT-Sheet.pdf" target="_blank">ACT Sheet for decreased C0 (carnitine uptake defect [CUD; primary carnitine deficiency])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C0-Algorithm.pdf" target="_blank">ACMG algorithm for carnitine uptake defect (decreased C0 [free carnitine])</a></li> </ul> </td> </tr> <tr> <td class="indent1">Carnitine (C0), elevated</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Carnitine palmitoyltransferase type I <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/C0_C16+C18.pdf" target="_blank">ACT Sheet for elevated C0/C16+C18 acylcarnitine (carnitine palmitoyltransferase I deficiency [CPT I])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C0-C16-C18-Elevated-Algorithm.pdf" target="_blank">ACMG algorithm for CPT1 (elevated C0 +/– C0/[C16+C18])</a></li> </ul> </td> </tr> <tr> <td class="indent1">Propionylcarnitine (C3)</td> <td>MS/MS</td> <td> <ul> <li>Propionic acidemia (propionyl-CoA carboxylase <span class="nowrap_whitespace">deficiency)<sup>§</sup></span></li> <li>Multiple carboxylase deficiency (holocarboxylase <span class="nowrap_whitespace">deficiency)<sup>§</sup></span></li> <li>Methylmalonyl-CoA mutase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Cobalamin metabolism defect complementation types A/B</li> </ul> </td> <td> <ul> <li>Cobalamin metabolism defect complementation <span class="nowrap_whitespace">types C/D<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Cobalamin metabolism defect complementation type F</li> <li>Transcobalamin receptor defect</li> <li>Untreated maternal vitamin B12 defect</li> </ul> </td> <td> <ul> <li>Methylmalonic acid</li> <li>Methylcitric acid</li> <li>Total homocysteine</li> </ul> </td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Elevated-C3-Acylcarnitine-PA-and-MA.aspx" target="_blank">ACT Sheet for elevated C3 acylcarnitine (propionic acidemia and methylmalonic acidemia)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C3-Algorithm.pdf" target="_blank">ACMG algorithm for elevated C3 (isolated)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Formiminoglutamic acid (FIGLU)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Short-chain acyl-CoA dehydrogenase deficiency</li> <li>Isobutyryl-CoA dehydrogenase deficiency</li> </ul> </td> <td> <ul> <li>Glutamate formiminotransferase deficiency (FIGLUuria)</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Newborn-Screening-ACT-Sheet-Elevated-C4-AcylcarnitineShort-Chain-Acyl-CoA-Dehydrogenase-SCAD-Deficie.aspx" target="_blank">ACT Sheet for elevated C4 acylcarnitine (short-chain acyl-CoA dehydrogenase [SCAD] deficiency)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C4-Elevated-Algorithm.pdf" target="_blank">ACMG algorithm for SCAD deficiency (elevated C4)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Butyryl-/isobutyrylcarnitine (C4)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Short-chain acyl-CoA dehydrogenase deficiency</li> <li>Isobutyryl-CoA dehydrogenase deficiency</li> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Ethylmalonic encephalopathy</li> <li>Glutamate formiminotransferase deficiency (FIGLUuria)</li> </ul> </td> <td> <ul> <li>Ethylmalonic acid</li> </ul> </td> <td> <ul> <li>Urine acylglycines</li> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> <li>Urine acylcarnitines</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Newborn-Screening-ACT-Sheet-Elevated-C4-AcylcarnitineShort-Chain-Acyl-CoA-Dehydrogenase-SCAD-Deficie.aspx" target="_blank">ACT Sheet for elevated C4 acylcarnitine (short-chain acyl-CoA dehydrogenase [SCAD] deficiency)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C4-Elevated-Algorithm.pdf" target="_blank">ACMG algorithm for SCAD deficiency (elevated C4)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Tiglylcarnitine (C5:1)</td> <td>MS/MS</td> <td> <ul> <li>Beta-ketothiolase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency (HSD10 disease)</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> <li>Urine acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Newborn-Screening-ACT-Sheet-Elevated-C5-OH-AcylcarnitineOrganic-Acidemias.aspx" target="_blank">ACT Sheet for elevated C5-OH acylcarnitine (organic acidemias)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf" target="_blank">ACMG algorithm for Organic acidemias (elevated C5-OH)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Isovaleryl-/2-methylbutyrylcarnitine (C5)</td> <td>MS/MS</td> <td> <ul> <li>Isovaleric <span class="nowrap_whitespace">acidemia<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>2-methylbutyrylglycinuria</li> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Ethylmalonic encephalopathy</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Urine acylglycines</li> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/C5.pdf" target="_blank">ACT Sheet for elevated C5 acylcarnitine (isovaleric acidemia)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C5-Algorithm.pdf" target="_blank">ACMG algorithm for isovaleric acidemia (increased C5 [isolated])</a></li> </ul> </td> </tr> <tr> <td class="indent1">OH butyrylcarnitine (C4-OH)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Short-/medium-chain acyl-CoA dehydrogenase deficiency</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/C4-OH.pdf" target="_blank">ACT Sheet for elevated C4-OH acylcarnitine (short-chain hydroxyacyl-Co-A dehydrogenase [SCHAD] deficiency)</a></li> <li><a href="http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Short Chain Hydroxyacyl-CoA Dehydrogenase (SCHAD) Deficiency Newborn Screening Algorithm.aspx" target="_blank">ACMG algorithm for elevated C4-OH (SCHAD deficiency)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Hexanoylcarnitine (C6)</td> <td>MS/MS</td> <td> <ul> <li>Medium-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine acylglycines</li> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">OH isovalerylcarnitine (C5-OH)</td> <td>MS/MS</td> <td> <ul> <li>3-methylcrotonyl-CoA carboxylase deficiency</li> <li>3-hydroxy-3-methylglutaryl-coenzyme A lyase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Beta-ketothiolase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Multiple carboxylase deficiency (holocarboxylase <span class="nowrap_whitespace">deficiency)<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency (HSD10 disease)</li> <li>3-methylglutaconic aciduria type I</li> </ul> </td> <td> <ul> <li>MT-ATP6-related mitochondrial disease</li> <li>Biotinidase deficiency (partial)</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> <li>Urine acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Newborn-Screening-ACT-Sheet-Elevated-C5-OH-AcylcarnitineOrganic-Acidemias.aspx" target="_blank">ACT Sheet for elevated C5-OH acylcarnitine (organic acidemias)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C5-OH-Elevated.pdf" target="_blank">ACMG algorithm for organic acidemias (elevated C5-OH)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Octanoylcarnitine (C8)</td> <td>MS/MS</td> <td> <ul> <li>Medium-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> <li>Medium-chain 3-ketoacyl-CoA thiolase deficiency</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine acylglycines</li> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/C8-C6-C10.pdf" target="_blank">ACT Sheet for elevated C8 with lesser elevations of C6 and C10 acylcarnitine (medium-chain acyl-CoA dehydrogenase [MCAD] deficiency)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C8-C6-C10-Algorithm.pdf" target="_blank">ACMG algorithm for elevated C8 and lesser elevations of C6 and C10</a></li> </ul> </td> </tr> <tr> <td class="indent1">Malonyl-/OH octanoylcarnitine (C3DC)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Malonyl-CoA decarboxylase deficiency</li> <li>Medium-chain 3-ketoacyl-CoA thiolase deficiency</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/C3-DC.pdf" target="_blank">ACT Sheet for elevated C3-DC acylcarnitine (malonic acidemia)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C3-DC-Algorithm.pdf" target="_blank">ACMG algorithm for malonic acidemia (elevated C3-DC)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Decadienoylcarnitine (C10:2)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>2;4-Dienoyl-CoA reductase deficiency</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma acylcarnitines</li> <li>Plasma amino acids</li> </ul> </td> <td>Next business day</td> <td>N/A</td> </tr> <tr> <td class="indent1">Decenoylcarnitine (C10:1)</td> <td>MS/MS</td> <td> <ul> <li>Medium-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine acylglycines</li> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Decanoylcarnitine (C10)</td> <td>MS/MS</td> <td> <ul> <li>Medium-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine acylglycines</li> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Succinyl-/methylmalonylcarnitine (C4DC)</td> <td>MS/MS</td> <td> <ul> <li>Methylmalonyl-CoA mutase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Cobalamin metabolism defect complementation types A/B</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Succinyl-CoA synthase deficiency</li> </ul> </td> <td> <ul> <li>Methylmalonic acid</li> <li>Total homocysteine</li> </ul> </td> <td> <ul> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> </ul> </td> <td>Next business day</td> <td>N/A</td> </tr> <tr> <td class="indent1">Glutaryl-/OH decanoylcarnitine (C5DC)</td> <td>MS/MS</td> <td> <ul> <li>Glutaric acidemia type I (glutaryl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency)<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td> <ul> <li>Glutaric</li> <li>3-hydroxyglutaric acid</li> <li>2-hydroxyglutaric acid</li> </ul> </td> <td> <ul> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> <li>Urine acylcarnitines</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/C5-DC.pdf" target="_blank">ACT Sheet for elevated C5-DC acylcarnitine (glutaric acidemia type I [GA I])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C5-DC-Algorithm.pdf" target="_blank">ACMG algorithm for glutaric acidemia type I (GA I; elevated C5-DC)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Dodecanoylcarnitine (C12)</td> <td>MS/MS</td> <td> <ul> <li>Very-long-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Methylglutarylcarnitine (C6DC)</td> <td>MS/MS</td> <td> <ul> <li>3-hydroxy-3-methylglutaryl-coenzyme A lyase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Urine organic acids</li> <li>Plasma acylcarnitines</li> <li>Urine acylcarnitines</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Tetradecanedioylcarnitine (C14:2)</td> <td>MS/MS</td> <td> <ul> <li>Very-long-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Tetradecenoylcarnitine (C14:1)</td> <td>MS/MS</td> <td> <ul> <li>Very-long-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Tetradecanoylcarnitine (C14)</td> <td>MS/MS</td> <td> <ul> <li>Very-long-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> <li>Carnitine-acylcarnitine translocase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Carnitine palmitoyltransferase type II <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">OH tetradecanoylcarnitine (C14-OH)</td> <td>MS/MS</td> <td> <ul> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Palmitoleylcarnitine (C16:1)</td> <td>MS/MS</td> <td> <ul> <li>Very-long-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> <li>Carnitine-acylcarnitine translocase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Carnitine palmitoyltransferase type II <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Palmitoylcarnitine (C16)</td> <td>MS/MS</td> <td> <ul> <li>Very-long-chain acyl-CoA dehydrogenase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> <li>Carnitine-acylcarnitine translocase <span class="nowrap_whitespace">deficiency I<sup>§</sup></span></li> <li>Carnitine palmitoyltransferase type II <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">OH hexadecenoylcarnitine (C16:1-OH)</td> <td>MS/MS</td> <td> <ul> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">OH palmitoylcarnitine (C16-OH)</td> <td>MS/MS</td> <td> <ul> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">Oleylcarnitine (C18:1)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Carnitine-acylcarnitine translocase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Carnitine palmitoyltransferase type II <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Newborn-Screening-ACT-SheetElevated-C16-andor-C181-AcylcarnitineCarnitine-Palmitoyltransferase-2-CPT.aspx" target="_blank">ACT Sheet for increased C16 and/or C18:1 acylcarnitine (carnitine palmitoyltransferase II [CPT II] deficiency and carnitine acylcarnitine translocated [CACT] deficiency)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/C16-C18-Elevated-Algorithm.pdf" target="_blank">ACMG algorithm for elevated C16 +/– C18:1 (CPT II or CACT)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Stearylcarnitine (C18)</td> <td>MS/MS</td> <td>N/A</td> <td> <ul> <li>Glutaric acidemia <span class="nowrap_whitespace">type II<sup>§</sup></span></li> <li>Carnitine-acylcarnitine translocase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> <li>Carnitine palmitoyltransferase type II <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">OH oleylcarnitine (C18:1-OH)</td> <td>MS/MS</td> <td> <ul> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="indent1">OH stearylcarnitine (C18-OH)</td> <td>MS/MS</td> <td> <ul> <li>Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency/trifunctional protein <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Plasma total and free carnitine</li> <li>Plasma acylcarnitines</li> <li>Urine organic acids</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Enzymes</td> </tr> <tr> <td class="indent1">Biotinidase</td> <td>Fluorometry</td> <td> <ul> <li>Biotinidase deficiency</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Biotinidase in serum</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Biotinidase-Deficiency-ACT-Sheet.pdf" target="_blank">ACT Sheet for absent/reduced biotinidase activity (biotinidase deficiency)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Biotinidase-Algorithm.pdf" target="_blank">ACMG algorithm for biotinidase deficiency</a></li> </ul> </td> </tr> <tr> <td class="indent1">Galactose-1-phoshate uridyltransferase (GALT)</td> <td>Fluorometry</td> <td> <ul> <li>Galactose-1-phosphate uridyltransferase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td>N/A</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>GALT in RBCs</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="http://www.acmg.net/PDFLibrary/Classical-Galactosemia-ACT-Sheet.pdf" target="_blank">ACT Sheet for absent/reduced galactose-1-phosphate uridyltransferase (GALT; classic galactosemia)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/GALT-Algorithm.pdf" target="_blank">ACMG algorithm for galactosemia (GALT deficiency)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Acid alpha-glucosidase (GAA)</td> <td>MS/MS or fluorometry</td> <td> <ul> <li>Pompe disease</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Creatine</li> <li>Creatinine</li> </ul> </td> <td> <ul> <li>GAA in WBCs</li> <li>Glucotetrasaccharides in urine</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Pompe.aspx" target="_blank">ACT Sheet for Pompe disease (glycogen storage disease type III)</a></li> <li><a href="https://www.acmg.net/ACMG/ACMG/UploadedPDFS/PDFDocuments/Pompe-Algorithm.aspx" target="_blank">ACMG algorithm for Pompe disease (acid alpha-glucosidase deficiency)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Galactocerebrosidase (GALC)</td> <td>MS/MS or fluorometry</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Krabbe disease</li> </ul> </td> <td> <ul> <li>Psychosine (galactosylsphingosine)</li> </ul> </td> <td> <ul> <li>GALC in WBCs</li> <li>Psychosine in RBCs</li> <li>Molecular genetic analysis</li> </ul> </td> <td><span class="nowrap_whitespace">Immediately<sup>ΔΔ</sup></span></td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Krabbe-Infantile.pdf" target="_blank">ACT Sheet for decreased galactocerebrosidase, elevated psychosine (Krabbe disease [infantile form])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Krabbe-Later-Onset.pdf" target="_blank">ACT Sheet for decreased galactocerebrosidase, mildly elevated psychosine (Krabbe disease [late-onset form])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Krabbe-Algorithm.pdf" target="_blank">ACMG algorithm for Krabbe disease (galactocerebrosidase deficiency)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Alpha-iduronidase (IDUA)</td> <td>MS/MS or fluorometry</td> <td> <ul> <li>Mucopolysaccharidosis I</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Dermatan sulfate</li> <li>Heparan sulfate</li> </ul> </td> <td> <ul> <li>IDUA in WBCs</li> <li>Glycosaminoglycans in blood or urine</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/MPSI-ACT-Sheet.aspx" target="_blank">ACT Sheet for alpha-L-iduronidase deficiency/with or without glycosaminoglycans (GAG; mucopolysaccharidosis type 1 [MPS I])</a></li> </ul> </td> </tr> <tr> <td class="indent1">Iduronate-2-sulfatase (IDS)</td> <td>MS/MS or fluorometry</td> <td> <ul> <li>Mucopolysaccharidosis II</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Multiple sulfatase deficiency</li> </ul> </td> <td> <ul> <li>Dermatan sulfate</li> <li>Heparan sulfate</li> </ul> </td> <td> <ul> <li>IDS in WBCs</li> <li>Glycosaminoglycans in blood or urine</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/MPS-II.pdf" target="_blank">ACT Sheet for iduronate 2-sulfatase deficiency (mucopolysaccharidoses type II)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/MPS-II-Algorithm.pdf" target="_blank">ACMG algorithm for mucopolysaccharidosis type II (MPS II; decreased iduronate 2-sulfatase [I2S] activity)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Alpha-galactosidase A (GLA)</td> <td>MS/MS or fluorometry</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Fabry disease</li> </ul> </td> <td>N/A</td> <td> <ul> <li>GLA in WBCs</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/Fabry.pdf" target="_blank">ACT Sheet for decreased alpha-galactosidase A (Fabry disease)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Fabry-Algorithm.pdf" target="_blank">ACMG algorithm for alpha-galactosidase A (alpha-gal A) deficiency</a></li> </ul> </td> </tr> <tr> <td class="indent1">Acid beta-glucosidase (GBA)</td> <td>MS/MS or fluorometry</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Gaucher disease</li> </ul> </td> <td> <ul> <li>Glucopsychosine (glucosylsphingosine)</li> </ul> </td> <td> <ul> <li>GBA in WBCs</li> <li>Glucopsychosine in blood</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Gaucher.aspx" target="_blank">ACT Sheet for decreased beta-glucocerebrosidase (Gaucher disease)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/Gaucher-Algorithm.pdf" target="_blank">ACMG algorithm for Gaucher disease (decreased beta-glucocerebrosidase activity)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Acid sphingomyelinase (ASM)</td> <td>MS/MS</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Niemann-Pick disease A, B</li> </ul> </td> <td> <ul> <li>Lysosphingomyelin</li> </ul> </td> <td> <ul> <li>ASM in WBCs</li> <li>Lysosphingomyelin in blood</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="http://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/Acid Sphingomyelinase Deficiency (ASMD) Newborn Screening ACT Sheet.aspx" target="_blank">ACT Sheet for decreased acid sphingomyelinase (acid sphingomyelinase deficiency [ASMD])</a></li> <li><a href="https://www.acmg.net/PDFLibrary/ASMD-Algorithm.pdf" target="_blank">ACMG algorithm for acid sphingomyelinase deficiency (ASMD; decreased acid sphingomyelinase [ASM])</a></li> </ul> </td> </tr> <tr> <td class="indent1">Glucose-6-phosphate dehydrogenase (G6PD)</td> <td>Fluorometry</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Glucose-6 phosphate dehydrogenase deficiency</li> </ul> </td> <td>N/A</td> <td> <ul> <li>G6PD in RBCs</li> <li>Molecular genetic analysis</li> </ul> </td> <td>Immediately</td> <td>N/A</td> </tr> <tr> <td class="subtitle2_left" colspan="9">Other analytes</td> </tr> <tr> <td class="indent1">Total galactose</td> <td>Fluorometry</td> <td> <ul> <li>Galactose-1-phosphate uridyltransferase <span class="nowrap_whitespace">deficiency<sup>§</sup></span></li> </ul> </td> <td> <ul> <li>Galactokinase (GALK) deficiency</li> <li>UDP-galactose-4-epimerase (GALE) deficiency</li> <li>Galactose mutarotase (GALM) deficiency</li> </ul> </td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>GALT in RBCs</li> <li>Galactose-1-phosphate in RBCs</li> <li>GALK/GALE in RBCs</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="http://www.acmg.net/PDFLibrary/Galactose-ACT-Sheet.pdf" target="_blank">ACT Sheet for elevated total galactose with normal GALT enzyme activity (primary or secondary hypergalactosemia)</a></li> <li><a href="http://www.acmg.net/PDFLibrary/Hypergalactosemia-Algorithm.pdf" target="_blank">ACMG algorithm for primary or secondary hypergalactosemia (elevated galactose)</a></li> </ul> </td> </tr> <tr> <td class="indent1">Lysophosphatidylcholines (LPC)</td> <td>MS/MS</td> <td> <ul> <li>X-linked adrenoleukodystrophy</li> </ul> </td> <td>N/A</td> <td> <ul> <li>Zellweger spectrum disease</li> <li>Peroxisomal bifunctional protein</li> <li>Peroxisomal acyl-CoA oxidase (ACOX1) deficiency</li> </ul> </td> <td> <ul> <li>LPC</li> </ul> </td> <td> <ul> <li>Plasma very-long-chain fatty acids</li> </ul> </td> <td>Next business day</td> <td> <ul> <li><a href="https://www.acmg.net/ACMG/UploadedPDFS/PDFDocuments/X-ALD-ACT-Sheet.aspx" target="_blank">ACT Sheet for elevated lysophosphatidylcholines (X-linked adrenoleukodystrophy [X-ALD])</a></li> </ul> </td> </tr> <tr> <td class="indent1">Guanidinoacetate (GUAC), creatine (Cr), creatinine (Crea)</td> <td>MS/MS</td> <td>N/A</td> <td>N/A</td> <td> <ul> <li>Guanidinoacetate methyltransferase deficiency</li> <li>Arginine:glycine amidinotransferase deficiency</li> <li>Cerebral creatine deficiency syndrome 1</li> </ul> </td> <td>N/A</td> <td> <ul> <li>GUAC</li> <li>Creatine</li> <li>Creatinine in plasma or urine</li> </ul> </td> <td>Immediately</td> <td> <ul> <li><a href="https://www.acmg.net/PDFLibrary/GAMT.pdf" target="_blank">ACT Sheet for increased guanidinoacetate (guanidinoacetate methyltransferase deficiency)</a></li> <li><a href="https://www.acmg.net/PDFLibrary/GAMT-Algorithm.pdf" target="_blank">ACMG algorithm for GAMT deficiency (elevated guanidinoacetate)</a></li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Newborn screening markers for inborn errors of metabolism and their differential diagnoses. Conditions are categorized as much as possible based on the Recommended Uniform Screening Panel (RUSP), but also included are conditions not yet widely screened for. Second-tier tests are performed on the original newborn screening sample, are employed to clarify abnormal results for primary screening markers with poor specificity (overlapping reference and disease ranges), and determine if a screening result is reported as positive or negative. However, only few programs make use of these tests. Urgency of clinical follow-up is dependent on the likelihood that a condition can present shortly after birth and benefit of screening requires treatment initiation as early as possible.</div><div class="graphic_footnotes"><p>ACMG: American College of Medical Genetics and Genomics; MS/MS: tandem mass spectrometry; ATP: adenosine triphosphate; GTP: guanosine triphosphate; RBC: red blood cell; WBC: white blood cell.</p>
<p>* Core and secondary conditions based on recommendations by the <a href="https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp" target="_blank">US Secretary of Health and Human Services</a>.</p>
<p>¶ Conditions that are also identifiable by newborn screening using the respective markers but have not been recognized by Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) as core or secondary conditions.</p>
<p>Δ Tests performed in other than dried blood spot samples; requires additional routine tests (refer to ACMG ACT sheets and algorithms).</p>
<p>◊ Further information on follow-up requirements can be found from the <a href="https://www.acmg.net/ACMG/Medical-Genetics-Practice-Resources/ACT_Sheets_and_Algorithms.aspx" target="_blank">ACMG ACT sheets and algorithms</a>.</p>
<p>§ Conditions recognized, as of 2014, by the Society of Inherited Metabolic Disorders (SIMD) as time critical.<sup>[1]</sup></p>
<p>¥ Valine also typically elevated in maple syrup urine disease and reduced in branched-chain ketoacid dehydrogenase kinase deficiency.</p>
<p>‡ Methionine concentration in condition is low.</p>
<p>† Methionine concentration in condition may be low or normal.</p>
<p>** Newborns of mothers with poorly controlled or untreated phenylketonuria during pregnancy are not affected with phenylketonuria but may have suffered from the teratogenic effect of high phenylalanine concentrations in utero, resulting in maternal phenylketonuria syndrome.<sup>[2]</sup> Refer to UpToDate topic on phenylketonuria for further details.</p>
<p>¶¶ Detection is possible because of secondary carnitine deficiency of the newborn.</p>
ΔΔ If psychosine is markedly elevated; mild psychosine can be followed up on the next business day (refer to relevant ACT Sheets: <a href="https://www.acmg.net/PDFLibrary/Krabbe-Infantile.pdf" target="_blank">immediate</a> and <a href="https://www.acmg.net/PDFLibrary/Krabbe-Later-Onset.pdf" target="_blank">next day</a>).<sup>[3,4]</sup></div><div class="graphic_reference">References:
<ol>
<li>Society of Inherited Metabolic Disorders (SIMD) position statement: Identifying abnormal newborn screens requiring immediate notification of the health care provider. Available at: <a href="https://www.simd.org/Issues/SIMD%20NBS%20Critical%20Conditions%20policy%20statement.pdf" target="_blank">https://www.simd.org/Issues/SIMD%20NBS%20Critical%20Conditions%20policy%20statement.pdf</a> (Accessed on September 18, 2022).</li>
<li>Grohmann-Held K, Burard P, Baerwald CGO, et al. Impact of pregnancy planning and preconceptual dietary training on metabolic control and offspring's outcome in phenylketonuria. J Inherit Med Dis 2022; 45:1070.</li>
<li>Guenzel AJ, Turgeon CT, Nickander KK, et al. The critical role of psychosine in screening, diagnosis, and monitoring of Krabbe disease. Genet Med 2020; 22:1108.</li>
<li>Thompson-Stone R, Ream MA, Gelb M, et al. Consensus recommendations for the classification and long-term follow up of infants who screen positive for Krabbe Disease. Mol Genet Metab 2021; 134:53.</li>
</ol>
<p class="extra_spacing_top">Adapted from:</p>
<ol>
<li>Matern D, Wilcken B, Rinaldo P. Newborn screening for inborn errors of metabolism. In: Inborn Metabolic Diseases: Diagnosis and Treatment, 5th ed, Saudubray J-M, van den Berghe G, Walter JH (Eds), Springer-Verlag 2012.</li>
<li>Greene C, Matern D. Newborn screening for inborn errors of metabolism. In: Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases, Blau N, Duran M, Gibson KM (Eds), Springer-Verlag 2014.</li>
</ol></div><div id="graphicVersion">Graphic 140207 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
